Shirvani Armin, Hassanizadeh Raheleh, Asgary Saeed
Iranian Center for Endodontic Research, Research Institute of Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran;
Knowledge Management Unit, Research Institute for Dental Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran Endod J. 2014 Spring;9(2):83-8. Epub 2014 Mar 8.
The aim of this quantitative systematic review/meta-analysis was to compare the treatment outcomes of mineral trioxide aggregate (MTA) and calcium hydroxide (CH) in pulpotomy of human primary molars. The focused PICO question was "in case of pulp exposure in vital primary molars, how does MTA pulpotomy compare to CH in terms of clinical/radiographic success?"
We retrieved published randomized clinical trials (RCTs) of at least 6-month duration; our search included articles published up to March 2013 in five following databases: PubMed (Medline), Cochrane database of systematic reviews, Science Citation Index, EMBASE, and Google Scholar. Mantel Haenszel and Inverse Variance-weighted methods were applied by STATA; the relative risk (RR) was calculated with 95% confidence intervals (CI).
A total of 282 English articles were collected. Two authors independently screened the articles and five RCTs were selected; data extraction and quality assessment were then carried out. Four RCTs were appropriate for meta-analysis according to their follow-up times by Mantel Haenszel method. Statistically significant difference was found between success rate of MTA compared to CH, with RR=0.08 (95% CI, 0.02-0.39), RR=0.19 (95% CI, 0.08-0.46), and RR=0.38 (95% CI, 0.21-0.68) for 6-, 12-, and 24-month follow-ups, respectively. A significant difference was also observed for all included RCTs after analyses using the Inverse Variance-weighted method (RR=0.44; 95% CI, 0.27-0.72).
Systematic review/meta-analysis of included RCTs revealed that for pulpotomy of vital primary molars, MTA has better treatment outcomes compared to CH.
本定量系统评价/荟萃分析的目的是比较无机三氧化物聚合体(MTA)和氢氧化钙(CH)用于人类乳磨牙牙髓切断术的治疗效果。聚焦的PICO问题是“在活髓乳磨牙牙髓暴露的情况下,MTA牙髓切断术与CH在临床/影像学成功率方面相比如何?”
我们检索了持续时间至少为6个月的已发表随机临床试验(RCT);检索范围包括截至2013年3月在以下五个数据库中发表的文章:PubMed(Medline)、Cochrane系统评价数据库、科学引文索引、EMBASE和谷歌学术。由STATA应用曼特尔-亨泽尔法和逆方差加权法;计算相对风险(RR)及95%置信区间(CI)。
共收集到282篇英文文章。两位作者独立筛选文章,选取了5项RCT;随后进行数据提取和质量评估。根据曼特尔-亨泽尔法,4项RCT因其随访时间适合进行荟萃分析。发现MTA与CH的成功率之间存在统计学显著差异,6个月、12个月和24个月随访时的RR分别为0.08(95%CI,0.02 - 0.39)、0.19(95%CI,0.08 - 0.46)和0.38(95%CI,0.21 - 0.68)。使用逆方差加权法分析后,所有纳入的RCT也观察到显著差异(RR = 0.44;95%CI,0.27 - 0.72)。
对纳入的RCT进行系统评价/荟萃分析表明,对于活髓乳磨牙的牙髓切断术,MTA的治疗效果优于CH。